Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2007

01.04.2007

Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases

verfasst von: Kuniya Tanaka, MD, PhD, Hiroshi Shimada, MD, PhD, Michio Ueda, MD, Kenichi Matsuo, MD, Itaru Endo, MD, PhD, Shinji Togo, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

We investigated factors affecting 5-year survival in patients undergoing hepatic resection for colorectal cancer metastases, including events long after initial hepatectomy. Although retrospective studies have demonstrated survival benefit of hepatectomy for metastatic colorectal cancer, few have included sufficient 5-year survivors to identify survival-related factors throughout the clinical course.

Methods

We divided 156 patients with hepatectomy for colorectal cancer metastases into 5-year survivors (n = 64) and patients dying before 5 years after hepatectomy (n = 92). Clinicopathologic data were compared retrospectively with respect to long-term outcome.

Results

By multivariate analysis, large liver tumors (adjusted relative risk, 2.029; P = .011), short tumor doubling time (1.809; P = .026), and origin from poorly differentiated primary adenocarcinoma (12.632; P = .001) compromised survival, whereas initial treatment-related variables did not. Although no difference was seen in initial treatment-related variables between 5-year survivors with recurrence after hepatectomy and patients dying before 5 years, repeat surgery was used more frequently in survivors (P < .001), typically with adjuvant chemotherapy.

Conclusions

Reoperations for each recurrence of metastases, followed by additional chemotherapy, frequently resulted in long survival.
Literatur
1.
Zurück zum Zitat Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of indications for resection. Surgery 1988;103:278–88 Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of indications for resection. Surgery 1988;103:278–88
2.
Zurück zum Zitat Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef
3.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC, et al. Association Francaise de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77:1254–62PubMedCrossRef Nordlinger B, Guiguet M, Vaillant JC, et al. Association Francaise de Chirurgie. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77:1254–62PubMedCrossRef
4.
Zurück zum Zitat Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938–46PubMed Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938–46PubMed
5.
Zurück zum Zitat Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231:487–99PubMedCrossRef Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231:487–99PubMedCrossRef
6.
Zurück zum Zitat Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery 1994; 116:703–11PubMed Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery 1994; 116:703–11PubMed
7.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–21PubMedCrossRef Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–21PubMedCrossRef
8.
Zurück zum Zitat Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84:977–80PubMedCrossRef Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84:977–80PubMedCrossRef
9.
Zurück zum Zitat Sugawara Y, Yamamoto J, Yamasaki S, Shimada K, Kosuge T, Makuuchi M. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery 2001; 129:408–13PubMed Sugawara Y, Yamamoto J, Yamasaki S, Shimada K, Kosuge T, Makuuchi M. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery 2001; 129:408–13PubMed
10.
Zurück zum Zitat Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278–84PubMed Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278–84PubMed
11.
Zurück zum Zitat Scheele J, Stangl R, Altendorf-Hofmann A, Gall F. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13–29PubMed Scheele J, Stangl R, Altendorf-Hofmann A, Gall F. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110:13–29PubMed
12.
Zurück zum Zitat Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg 1987; 205:264–70PubMedCrossRef Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg 1987; 205:264–70PubMedCrossRef
13.
Zurück zum Zitat Stone MD, Cady B, Jenkins RL, McDermott WV, Steele GD Jr. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 1990; 125:718–22PubMed Stone MD, Cady B, Jenkins RL, McDermott WV, Steele GD Jr. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 1990; 125:718–22PubMed
14.
Zurück zum Zitat Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51–60PubMedCrossRef Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51–60PubMedCrossRef
15.
Zurück zum Zitat Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Moriya Y, Sugihara K. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178:275–81PubMedCrossRef Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Moriya Y, Sugihara K. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178:275–81PubMedCrossRef
16.
Zurück zum Zitat Suzuki S, Sakaguchi T, Yokoi Y, et al. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129:421–8PubMed Suzuki S, Sakaguchi T, Yokoi Y, et al. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129:421–8PubMed
17.
Zurück zum Zitat Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases. The third hepatectomy. Ann Surg 2003; 238:871–84PubMedCrossRef Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases. The third hepatectomy. Ann Surg 2003; 238:871–84PubMedCrossRef
18.
Zurück zum Zitat Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88:980–5PubMedCrossRef Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88:980–5PubMedCrossRef
19.
Zurück zum Zitat Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–22PubMedCrossRef Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–22PubMedCrossRef
20.
Zurück zum Zitat Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777–85PubMedCrossRef Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777–85PubMedCrossRef
21.
Zurück zum Zitat Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–9PubMedCrossRef Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–9PubMedCrossRef
22.
Zurück zum Zitat Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001; 8:347–53PubMedCrossRef Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001; 8:347–53PubMedCrossRef
23.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30PubMedCrossRef Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23–30PubMedCrossRef
24.
Zurück zum Zitat Yamanaka N, Okamoto E, Oriyama T, et al. A prediction scoring system to select the surgical treatment of liver cancer: further refinement based on 10 years of use. Ann Surg 1994; 219:342–6PubMedCrossRef Yamanaka N, Okamoto E, Oriyama T, et al. A prediction scoring system to select the surgical treatment of liver cancer: further refinement based on 10 years of use. Ann Surg 1994; 219:342–6PubMedCrossRef
25.
Zurück zum Zitat Terminology Committee of the International Hepato-Pancreato-Biliary Association. Brisbane 2000 terminology of liver anatomy and resection. HPB 2000; 2:333–9 Terminology Committee of the International Hepato-Pancreato-Biliary Association. Brisbane 2000 terminology of liver anatomy and resection. HPB 2000; 2:333–9
26.
Zurück zum Zitat Couinaud C. Lobes et segments hépatiques: notes sur l’architecture anatomique et chirurgicale du foie. Presse Med 1954; 62:709–12PubMed Couinaud C. Lobes et segments hépatiques: notes sur l’architecture anatomique et chirurgicale du foie. Presse Med 1954; 62:709–12PubMed
27.
Zurück zum Zitat Healey JE, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts. Arch Surg 1953; 66:599–616 Healey JE, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts. Arch Surg 1953; 66:599–616
28.
Zurück zum Zitat Collins VP, Loeffier RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol 1956; 76:988–1000 Collins VP, Loeffier RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol 1956; 76:988–1000
29.
Zurück zum Zitat Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982; 46:773–81PubMed Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R. Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 1982; 46:773–81PubMed
30.
Zurück zum Zitat Havelaar IJ, Sugerbaker PH, Vermes M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer 1984; 54:163–71PubMedCrossRef Havelaar IJ, Sugerbaker PH, Vermes M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer 1984; 54:163–71PubMedCrossRef
31.
Zurück zum Zitat Fujii S. Hepatic metastases development from colorectal cancer in view of CEA doubling time. Yokohama Igaku 1994; 45:627–35 (in Japanese with English abstract) Fujii S. Hepatic metastases development from colorectal cancer in view of CEA doubling time. Yokohama Igaku 1994; 45:627–35 (in Japanese with English abstract)
32.
Zurück zum Zitat Shimada H, Nanko M, Fujii S, et al. Treatment strategies for hepatic metastasis from colorectal cancer. J Hepatobiliary Pancreat Surg 1995; 2:116–21CrossRef Shimada H, Nanko M, Fujii S, et al. Treatment strategies for hepatic metastasis from colorectal cancer. J Hepatobiliary Pancreat Surg 1995; 2:116–21CrossRef
33.
Zurück zum Zitat Watine J, Miédougé M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases. Dis Colon Rectum 2001; 44:1791–9PubMedCrossRef Watine J, Miédougé M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases. Dis Colon Rectum 2001; 44:1791–9PubMedCrossRef
34.
Zurück zum Zitat Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216:493–504PubMedCrossRef Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216:493–504PubMedCrossRef
35.
Zurück zum Zitat Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647–51PubMed Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647–51PubMed
36.
Zurück zum Zitat Koga H, Moriya Y, Akasu T, Fujita S. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 1999; 25:292–6PubMedCrossRef Koga H, Moriya Y, Akasu T, Fujita S. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 1999; 25:292–6PubMedCrossRef
37.
Zurück zum Zitat Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: the most important pre-hepatectomy predictor of survival and non-recurrence in hepatic colorectal cancer metastasis. World J Surg 2004; 28:263–70PubMedCrossRef Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: the most important pre-hepatectomy predictor of survival and non-recurrence in hepatic colorectal cancer metastasis. World J Surg 2004; 28:263–70PubMedCrossRef
38.
Zurück zum Zitat Lorenz M, Müller H, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998; 228:756–64PubMedCrossRef Lorenz M, Müller H, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998; 228:756–64PubMedCrossRef
39.
Zurück zum Zitat Onaitis M, Morse M, Hurwitz H, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 2003; 237:782–9PubMedCrossRef Onaitis M, Morse M, Hurwitz H, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 2003; 237:782–9PubMedCrossRef
40.
Zurück zum Zitat Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039–48PubMedCrossRef Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039–48PubMedCrossRef
41.
Zurück zum Zitat Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395–403PubMedCrossRef Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395–403PubMedCrossRef
42.
Zurück zum Zitat Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004; 78:238–44PubMedCrossRef Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004; 78:238–44PubMedCrossRef
43.
Zurück zum Zitat Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef
44.
Zurück zum Zitat Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11:541–7PubMedCrossRef Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11:541–7PubMedCrossRef
45.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66PubMedCrossRef
46.
Zurück zum Zitat Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef
47.
Zurück zum Zitat Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531–5 Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531–5
48.
Zurück zum Zitat De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed
49.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRef Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRef
50.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef
51.
Zurück zum Zitat Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000–5PubMedCrossRef Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000–5PubMedCrossRef
52.
Zurück zum Zitat Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501–18PubMed Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501–18PubMed
53.
Zurück zum Zitat Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRef Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRef
54.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef
55.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45PubMedCrossRef Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45PubMedCrossRef
Metadaten
Titel
Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases
verfasst von
Kuniya Tanaka, MD, PhD
Hiroshi Shimada, MD, PhD
Michio Ueda, MD
Kenichi Matsuo, MD
Itaru Endo, MD, PhD
Shinji Togo, MD, PhD
Publikationsdatum
01.04.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9071-3

Weitere Artikel der Ausgabe 4/2007

Annals of Surgical Oncology 4/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.